A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

~49 mi. (Bellinzona, Switzerland, +93 more cities)

Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1604)

Clear Cell Renal Cell Carcinoma

belzutifan, +1 more drug

targeted therapy

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

~49 mi. (Bellinzona, Switzerland, +150 more cities)

Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1921)

Head and Neck Squamous Cell Carcinoma

cisplatin, +2 more drugs

chemotherapy, +2 more types

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

~49 mi. (Bellinzona, Switzerland, +105 more cities)

Ospedale Regionale di Bellinzona e Valli ( Site 1407)

ATM Loss, +62 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib

targeted therapy

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)

~49 mi. (Bellinzona, Switzerland, +76 more cities)

Ospedale Regionale Bellinzona e Valli ( Site 2203)

Non-Small Cell Lung Carcinoma

docetaxel, +1 more drug

chemotherapy, +1 more type

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

~49 mi. (Bellinzona, Switzerland, +52 more cities)

Ospedale Regionale di Bellinzona e Valli - Bellinzona

MS4A1 Expression, +1 more biomarker

Blastoid Variant Mantle Cell Lymphoma, +12 more conditions

pirtobrutinib, +3 more drugs

chemotherapy, +2 more types

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

~49 mi. (Bellinzona, Switzerland, +34 more cities)

Istituto Oncologico della Svizzera Italiana (IOSI)

MS4A1 Expression

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, +2 more conditions

ibrutinib, +1 more drug

immunotherapy, +1 more type

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

~49 mi. (Bellinzona, Switzerland, +15 more cities)

Ospedale Regionale di Bellinzona e Valli

ARID1A Loss, +125 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +7 more conditions

elimusertib, +1 more drug

immunotherapy, +1 more type

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

~51 mi. (Varese, Italy, +18 more cities)

ASST Sette Laghi

EGFR A763_Y764insFQEA, +11 more biomarkers

Non-Small Cell Lung Carcinoma

dacomitinib, +1 more drug

targeted therapy

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

~55 mi. (Cordona, Italy, +28 more cities)

C.H. Regional Reina Sofia - PPDS

Malignant Solid Tumor

atezolizumab, +1 more drug

immunotherapy

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

~63 mi. (Ponderano, Italy, +383 more cities)

Ospedale Degli Infermi Di Biella; Reparto Oncologia Medica

ER Negative, +2 more biomarkers

Breast Carcinoma

atezolizumab, +4 more drugs

chemotherapy, +1 more type

CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer

~65 mi. (Como, Italy, +64 more cities)

ASST Lariana - Ospedale S. Anna

ER Positive, +1 more biomarker

Breast Carcinoma

anastrozole, +2 more drugs

hormone therapy

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

~68 mi. (Via Manzoni, Italy, +31 more cities)

IRCCS istituto Clinico Humanitas U.O. di Oncologia ed Ematologia

Diffuse Large B-Cell Lymphoma, +1 more condition

ibrutinib, +1 more drug

chemotherapy, +2 more types